Stock AnalizEton Pharmaceuticals, Inc. ETON
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Eton Pharmaceuticals, Inc. (ETON) is a healthcare company listed in the US with a market value of about $1.8B. In the twelve months to September 30, 2026 it had revenue of $141M and net income of $50M, a net margin of 35.3%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (5/5); the weakest is value (0/5).
Key numbers: a P/E of 42.6, a price to free cash flow of 48.2, 5-year revenue growth of 360% a year, a 5-year average ROIC of -12%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 73% below the current price.
Score: 2.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $141M | $80M | $39M | $32M | $21M | $22M | $39000 | $959000 | — |
| Net income | $50M | -$5M | -$4M | -$936000 | -$9M | -$2M | -$28M | -$18M | -$13M |
| Free cash flow | $38M | $10M | $943000 | $7M | $5M | -$5M | -$22M | -$19M | -$8M |
| EPS (diluted) | $1.50 | $-0.17 | $-0.15 | $-0.04 | $-0.36 | $-0.08 | $-1.33 | $-1.03 | $-5.80 |
| Net margin | 35.3% | -5.8% | -9.8% | -3.0% | -42.4% | -8.9% | -71717.9% | -1910.3% | — |
| ROIC | — | -1.2% | -3.8% | -4.5% | -44.3% | -6.5% | -88.3% | -97.3% | -31.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $80.75, 26% above the current price; targets range from $80.00 to $82.00; the consensus rating is “Strong buy”; expected EPS is $1.77 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Eton Pharmaceuticals’s P/E ratio?
About 42.6, based on the last twelve months of diluted earnings per share (forward P/E about 20.9).
Is Eton Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 73% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Eton Pharmaceuticals pay a dividend?
Not currently.
Is Eton Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Eton Pharmaceuticals scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.